Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes

被引:76
作者
Izumi, H [1 ]
Takahashi, C [1 ]
Oh, J [1 ]
Noda, M [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan
关键词
ras oncogene; transformation suppressor gene; tissue factor pathway inhibitor-2; matrix metalloproteinase-2; tumor invasion;
D O I
10.1016/S0014-5793(00)01902-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A human placenta cDNA expression library was screened for genes inducing flat reversion when transfected into a v-K-ras-transformed NIH3T3 cell line, DT. One such gene was found to encode a Kunitz-type serine protease inhibitor, tissue factor pathway inhibitor-2 (TFPI-2), While the TFPI-2 mRNA can be detected in normal human fibroblasts (MRC-5), it is down-regulated in MRC-5 cells expressing an activated H-ras oncogene and in the human fibrosarcoma cell line, HT1080. Restored expression of the TFPI-2 gene in HT1080 cells resulted in the suppression of matrix invasion activity in vitro with concomitant decrease in the relative amount of active matrix metalloproteinase-2 secreted from the cells. When DT cells were cultured in the presence of conditioned medium and extracellular matrix prepared from TFPI-2-transfected HT1080 cells, increased attachment and flat reversion were observed. These results suggest that TFPI-2 may be required for the maintenance of the integrity of extracellular matrix in normal tissues and its down-regulation as a result of oncogene activation may contribute to the malignant phenotypes of tumor cells. (C) 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 38 条
[1]  
AKAO S, 1988, VIRCHOWS ARCH B, V55, P293
[2]   Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation [J].
Baramova, EN ;
Bajou, K ;
Remacle, A ;
LHoir, C ;
Krell, HW ;
Weidle, UH ;
Noel, A ;
Foidart, JM .
FEBS LETTERS, 1997, 405 (02) :157-162
[3]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[4]   All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral [J].
Bos, JL .
EMBO JOURNAL, 1998, 17 (23) :6776-6782
[5]  
BOS JL, 1989, CANCER RES, V49, P4682
[6]   MECHANISM OF ACTIVATION OF AN N-RAS GENE IN THE HUMAN FIBRO-SARCOMA CELL-LINE HT1080 [J].
BROWN, R ;
MARSHALL, CJ ;
PENNIE, SG ;
HALL, A .
EMBO JOURNAL, 1984, 3 (06) :1321-1326
[7]   TISSUE FACTOR PATHWAY INHIBITOR AND THE REVISED THEORY OF COAGULATION [J].
BROZE, GJ .
ANNUAL REVIEW OF MEDICINE, 1995, 46 :103-112
[8]   PURIFICATION AND CHARACTERIZATION OF PLACENTAL PROTEIN-5 [J].
BUTZOW, R ;
HUHTALA, ML ;
BOHN, H ;
VIRTANEN, I ;
SEPPALA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 150 (01) :483-490
[9]   ACTIVATION OF KI-RAS 2 GENE IN HUMAN-COLON AND LUNG CARCINOMAS BY 2 DIFFERENT POINT MUTATIONS [J].
CAPON, DJ ;
SEEBURG, PH ;
MCGRATH, JP ;
HAYFLICK, JS ;
EDMAN, U ;
LEVINSON, AD ;
GOEDDEL, DV .
NATURE, 1983, 304 (5926) :507-513
[10]   p52(PAI-1) gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: Mechanism of induction and involvement in the morphological response [J].
Higgins, PJ ;
Ryan, MP ;
Jelley, DM .
BIOCHEMICAL JOURNAL, 1997, 321 :431-437